TGA-Standard Botanical Active Ingredients Screening
High-throughput bio-guided fractionation and target isolation optimized for Australian ARTG Listed and Assessed therapeutic formulations.
Explore ServiceTurnkey solutions tailored for Australian complementary medicine brands, pharmaceutical sponsors, and biomedical research institutions.
High-throughput bio-guided fractionation and target isolation optimized for Australian ARTG Listed and Assessed therapeutic formulations.
Explore Service
Fully validated HPTLC fingerprinting, HPLC-DAD, and GC-MS assay method development fulfilling TGO 92 and British Pharmacopoeia specifications.
Explore Service
Cellular metabolic assays, receptor binding affinity assays, and enzymatic pathway elucidations delivering verifiable MoA data for evidence dossiers.
Explore Service
Quantitative seasonal and geographic chemotypic variation studies to de-risk Australian supply chains and secure reliable high-yield biomass sources.
Explore ServiceNavigating the rigorous scientific benchmarks of the Therapeutic Goods Administration (TGA) while capturing growing consumer demand across Australasia.
Australia represents one of the most sophisticated and stringently regulated complementary medicine markets globally. Valued at over AUD $5.6 billion, the Australian consumer landscape demands evidence-based formulations, clean-label transparency, and verifiable efficacy. Under the legislative framework of the Therapeutic Goods Act 1989, therapeutic goods—encompassing herbal substances, phytochemical complexes, and botanical extracts—must be entered in the Australian Register of Therapeutic Goods (ARTG) before commercial supply.
For Australian sponsors and brand manufacturers, the fundamental hurdle remains the scientific burden of proof: differentiating between Listed Medicines (AUST L), Assessed Listed Medicines (AUST L(A)), and Registered Medicines (AUST R). While low-risk pre-approved ingredients are permissible for AUST L, establishing higher-level indications requires comprehensive, high-tier clinical evidence, validated chromatographic assay dossiers, and toxicological clearance.
Critical Insight for Australian Sponsors: Standard generic botanical extracts frequently fail TGA pre-clearance due to solvent residue limits, uncontrolled seasonal chemotype variations, and missing bio-guided potency assays. Active ingredients screening provides the required molecular and pharmacological substantiation to bridge lab innovation directly to ARTG listing.
MedGence functions as an ODM/CDMO scientific engine, empowering Australian brand owners, contract packagers, and research institutions to discover, validate, and standardize botanical molecules with full compliance under Therapeutic Goods Order No. 92 (TGO 92), TGO 100, and PIC/S GMP standards.
Combining AI molecular docking with multi-stage chromatographic fractionation to pinpoint novel therapeutic phytochemicals from complex botanical matrices.
Utilizing machine learning models trained on 400+ validated single-herb pharmacophores and 83 modernized classic formulations to forecast molecular receptor affinity prior to wet-lab extraction, slashing R&D lead time by over 60%.
Unbiased non-targeted metabolomics identification combined with targeted quantification. Dissects sub-fractions with sub-ppm mass accuracy to capture rare saponins, volatile terpenes, and conjugated polyphenols.
Iterative screening process pairing automated preparatory chromatography directly with high-content phenotypic cellular assays, isolating only the pure bioactive moieties responsible for clinical outcomes.
Multi-spectral satellite chemotyping of wild-crafted & cultivated crops to map harvest timing to active concentration peaks.
Automated 3D organoid & microfluidic organ-on-chip screening to mimic human absorption kinetics before pilot animal studies.
Subcritical water and low-energy co-solvent supercritical CO2 separation systems for 100% zero-organic-solvent finished ingredients.
End-to-end blockchain verified Certificate of Analysis (CoA) tied directly to Australian TGA Common Technical Document (CTD) formats.
Seamlessly bridging laboratory active discovery into metric-ton commercial extraction without loss of phytochemical potency or batch fidelity.
Unlike traditional batch vats that degrade thermosensitive compounds, our continuous counter-current dynamic extraction lines control dwell time to the second, optimizing extraction efficiency by 34% while maintaining thermal integrity.
Employing ceramic ultrafiltration and nano-membrane concentration modules to eliminate macromolecules, resins, and inorganic salts without harsh chemical precipitations, yielding crystal-clear reconstitution for oral liquid formulations.
By integrating raw botanical farm-gate procurement across China's geo-authentic producing regions (Daodi) with automated extraction and in-house CRO validation, we eliminate multiple intermediary margins for Australian partners.
Global disruptions and geopolitical shifts demand agile manufacturing. MedGence maintains an audited buffer supply of primary reference botanicals and duplicate automated extraction lines. Every batch manufactured is backed by full analytical retention samples stored for 5 years, guaranteeing long-term batch-to-batch traceability for ARTG compliance audits.
A transparent, stage-gated lifecycle eliminating development risk from target specification to commercial container clearance.
We review your proposed claim (e.g., cognitive health, metabolic regulation, joint comfort), cross-reference permissible ingredient databases under ARTG, and select optimal botanical candidates.
Extracting raw material samples across divergent harvest seasons, soil profiles, and plant parts (roots, leaves, bark) to pinpoint maximal active molecule concentration.
Establishing reproducible HPLC/GC/HPTLC testing methodologies and generating validated fingerprint spectra for QC release testing in Australia.
Execution of in vitro cell receptor assays, cytotoxicity screening, and GLP-compliant LD50/acute/genotoxicity evaluations confirming safety margins.
Transfer of extraction parameters to pilot reactors, followed by formulation into powders, softgels, two-piece hard capsules, or functional liquids.
Commercial batch production under strictly audited cleanrooms with full CTD module documentation ready for seamless submission to the TGA.
Select individual phase studies or engage our complete discovery-to-finished-product contract manufacturing lifecycle.
Systematic screening and quantification of bioactive alkaloids, flavonoids, and glycosides tailored to Australian therapeutic categories.
View Service Details
Development and ICH-validation of HPLC, HPTLC, and LC-MS fingerprint standards for quality and identity verification.
View Service Details
High-throughput bioassay screenings targeting inflammatory pathways, antioxidant potency, and metabolic enzymatic inhibition.
View Service Details
Comprehensive comparative botanical mapping isolating the highest yielding cultivars, harvest months, and regional origins.
View Service Details
Animal efficacy models and systemic toxicological evaluations ensuring full pre-clinical safety prior to human administration.
View Service Details
GCP-compliant human clinical trial execution generating high-level scientific evidence to defend Assessed Listed claims.
View Service Details
Scalable resin column chromatography and crystallization delivering active phytochemical standards from lab grams to pilot drums.
View Service Details
Multi-wavelength chromatographic pattern comparison ensuring chemical equivalence between development trials and commercial production.
View Service DetailsIn-depth technical answers addressing regulatory dossier preparation, chromatographic method validation, intellectual property, and import logistics.
Connect directly with our multidisciplinary scientific team in Changsha. Discuss target indications, request specialized chromatographic screening protocols, or commission custom OEM/CDMO active ingredient manufacturing.